<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461160</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-915-1001</org_study_id>
    <secondary_id>U1111-1168-6456</secondary_id>
    <nct_id>NCT02461160</nct_id>
  </id_info>
  <brief_title>Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study</brief_title>
  <official_title>A Phase 1 Safety, Tolerability, Pharmacokinetic, Placebo-Controlled and Open-Label Study of Escalating Single and Multiple Oral Doses, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Subjects of TAK-915 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, tolerability and plasma
      pharmacokinetic (PK) profile of TAK-915 when administered as single and multiple oral
      suspension doses at escalating dose levels in healthy participants, including elderly
      participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-915. TAK-915 is being tested to find a safe
      and well-tolerated dose. This study will look at the pharmacokinetic characteristics (how the
      drug acts throughout the body) of the drug and safety and tolerability (lab results, vital
      signs, ECG, and side effects) in healthy people (including elderly) who take TAK-915.

      The study will enroll a total of 88 patients. This study is designed to consist of 5
      different dosing schedules: single rising dose (SRD), multiple rising dose (MRD), drug-drug
      interaction (DDI), bioavailability and food effect (BA/FE), and Elderly Subject Single Dose
      (ESSD). The study population for SRD will consist of 48 participants enrolled into 6 cohorts.
      Each cohort will have 8 randomized participants, with 6 receiving a single dose of TAK-915,
      and 2 receiving matching placebo under fasted conditions. The starting dose is 30 mg. The
      dose for Cohorts 2 through 6 will be determined based on data collected from previous
      cohorts.

      The study population for MRD will consist of 32 participants enrolled into 4 cohorts. Each
      cohort will have 8 randomized participants, with 6 receiving one dose of TAK-915 on Day 1 and
      daily dosing on Days 8-14, and 2 receiving matching placebo under fasted conditions. The dose
      for each cohort in Part 2 will be determined based on data collected from completed SRD
      cohorts of the study.

      The study population for DDI will consist of 12 participants enrolled into 1 cohort. All
      participants will receive one dose of TAK-915 on Day 3 and daily dosing on Days 10-16 under
      fasted conditions. All participants will also receive a single dose of Midazolam 2 mg on Day
      1 and Day 16. The dose of TAK-915 in this cohort will be determined based on data collected
      from SRD cohorts and will be the same dose that is administered in MRD Cohort 8.

      The study population for BA/FE will consist of 12 participants enrolled into 1 cohort.
      TAK-915 will be administered in 3 single-dose regimens in a 3-way crossover design using 50
      mg oral dose treatments (Regimen A: TAK915 50 mg oral suspension formulation in fasted state;
      Regimen B: TAK-915 50 tablet formulation in fasted state; Regimen C: TAK-915 50 tablet
      formulation in fasted state). TAK-915 dosing will occur on Day 1 of each treatment period
      followed by a 14 day washout period.

      The study population for ESSD will consist of 8 elderly participants (ages 65-75 years)
      enrolled into 1 cohort. All 8 participants will receive a single dose of TAK-915 50 mg
      suspension under fasted conditions.

      This single-center trial will be conducted in the United States. The overall time to
      participate in this study is up to 70 days. Participants will make multiple visits to the
      clinic including a period of confinement to the clinic and will be contacted by telephone 12
      days after the last dose of study drug for a follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2015</start_date>
  <completion_date type="Actual">August 1, 2016</completion_date>
  <primary_completion_date type="Actual">August 1, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)</measure>
    <time_frame>Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Markedly Abnormal Safety Laboratory Tests</measure>
    <time_frame>Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)</time_frame>
    <description>The percentage of participants with any markedly abnormal standard safety laboratory values, including haematology, serum chemistries, or urinalysis, during the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Markedly Abnormal Vital Sign Measurements</measure>
    <time_frame>Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)</time_frame>
    <description>The percentage of participants who meet markedly abnormal criteria for vital signs after dosing, including oral body temperature (temp.), respiration rate, pulse rate (PR) Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) for assessment in positions of supine or standing. Vital signs were considered abnormal if they were beyond the values defined in categories.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Markedly Abnormal Values of 12-Lead Electrocardiogram (ECG) Parameters</measure>
    <time_frame>Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)</time_frame>
    <description>The percentage of participants who meet markedly abnormal criteria for ECG parameters as specified by the protocol and statistical analysis plan during the treatment period. ECG parameters were considered abnormal if they were beyond the values defined in categories.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-915</measure>
    <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-915</measure>
    <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-915</measure>
    <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-915</measure>
    <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCâˆž: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-915</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rac(AUC): Accumulation Ratios Between Day 14 AUC(0-24) and Day 1 AUC(0-24) for TAK-915</measure>
    <time_frame>Days 1 and 14 pre-dose and at multiple time points (up to 96 hours) post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rac(Cmax): Accumulation Ratios Between Day 14 Cmax and Day 1 Cmax for TAK-915</measure>
    <time_frame>Days 1 and 14 pre-dose and at multiple time points (up to 96 hours) post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Dependency Assessment From AUC(0-24) After Last Dose for TAK-915 on Day 14 in MRD Cohorts Compared to AUC(0-inf) After a Single Dose on Day 1</measure>
    <time_frame>Days 1 and 14 pre-dose and at multiple time points (up to 96 hours) post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for Midazolam Alone (Day 1) and in the Presence of TAK-915 (Day 16) in DDI Cohort</measure>
    <time_frame>Days 1 and 16 pre-dose and at multiple timepoints (up to 24 hours) post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for Midazolam Alone (Day 1) and in the Presence of TAK-915 (Day 16) in DDI Cohort</measure>
    <time_frame>Days 1 and 16 pre-dose and at multiple timepoints (up to 24 hours) post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24) for Midazolam After Single Dose (Day 1)/AUC(0-24) for Midazolam After 7 Daily Doses of TAK-915 (Day 16) in DDI Cohort</measure>
    <time_frame>Days 1 and 16 pre-dose and at multiple timepoints (up to 24 hours) post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t1/2) for TAK-915</measure>
    <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Apparent Clearance for TAK-915</measure>
    <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) for TAK-915</measure>
    <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Drug Excreted in Urine (Ae) for TAK-915</measure>
    <time_frame>SRD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Drug Excreted in Urine (Fe) for TAK-915</measure>
    <time_frame>SRD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLr) for TAK-915</measure>
    <time_frame>SRD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-915 on Day 1 in DDI Cohort</measure>
    <time_frame>Days 1 at multiple time points (up to 96 hours) post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-915 on Day 1 in DDI Cohort</measure>
    <time_frame>Days 1 at multiple time points (up to 96 hours) post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tau): Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau Over a Dosing Interval Where Tau is the Length of the Dosing Interval for TAK-915 in DDI Cohort</measure>
    <time_frame>Days 16 at multiple time points (up to 96 hours) post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of TAK-915 Metabolite Cmax to TAK-915 Cmax in SRD and MRD Cohorts</measure>
    <time_frame>Day 1 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of TAK-915 Metabolite AUC(0-inf) to TAK-915 AUC(0-inf) in SRD Cohorts</measure>
    <time_frame>Day 1 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of TAK-915 Metabolite Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau Over a Dosing Interval [AUC(0-tau)] Where Tau is the Length of the Dosing Interval to TAK-915 AUC(0-tau) in MRD Cohorts</measure>
    <time_frame>Day 14 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</measure>
    <time_frame>Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</measure>
    <time_frame>Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</measure>
    <time_frame>Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</measure>
    <time_frame>Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t1/2) for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</measure>
    <time_frame>Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Î»z: Terminal Elimination Rate Constant for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</measure>
    <time_frame>Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>SRD Cohorts 1-3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-915 placebo-matching suspension, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD Cohort 1 TAK-915 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD Cohort 2: TAK-915 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRD Cohort 3: TAK-915 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD Cohorts 4-6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD Cohort 4: TAK-915 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD Cohort 5: TAK-915 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD Cohort 6: TAK-915 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DDI Cohort 7: TAK-915 + Midazolam 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA/FE Cohort 8 Group 1: A,B,C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1, followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3. Each period was separated out by a 6 to 14-day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA/FE Cohort 9 Group 1: B,C,A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1. Each period was separated out by a 6 to 14-day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA/FE Cohort 10 Group 1: C,A,B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1 followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2. Each period was separated out by a 6 to 14-day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESSD Cohort 11: TAK-915 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-915 suspension</intervention_name>
    <description>TAK-915 oral suspension</description>
    <arm_group_label>BA/FE Cohort 8 Group 1: A,B,C</arm_group_label>
    <arm_group_label>BA/FE Cohort 9 Group 1: B,C,A</arm_group_label>
    <arm_group_label>DDI Cohort 7: TAK-915 + Midazolam 2 mg</arm_group_label>
    <arm_group_label>ESSD Cohort 11: TAK-915 50 mg</arm_group_label>
    <arm_group_label>MRD Cohort 4: TAK-915 30 mg</arm_group_label>
    <arm_group_label>MRD Cohort 5: TAK-915 100 mg</arm_group_label>
    <arm_group_label>MRD Cohort 6: TAK-915 200 mg</arm_group_label>
    <arm_group_label>MRD Cohorts 4-6</arm_group_label>
    <arm_group_label>SRD Cohort 1 TAK-915 30 mg</arm_group_label>
    <arm_group_label>SRD Cohort 2: TAK-915 100 mg</arm_group_label>
    <arm_group_label>SRD Cohort 3: TAK-915 200 mg</arm_group_label>
    <arm_group_label>SRD Cohorts 1-3: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam oral solution</description>
    <arm_group_label>BA/FE Cohort 9 Group 1: B,C,A</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo-matching TAK-915 suspension</description>
    <arm_group_label>BA/FE Cohort 10 Group 1: C,A,B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-915 tablet</intervention_name>
    <description>TAK-915 tablet</description>
    <arm_group_label>ESSD Cohort 11: TAK-915 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the opinion of the investigator, the participant is capable of understanding and
             complying with protocol requirements.

          2. The participant or, when applicable, the participant's legally acceptable
             representative signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures including
             requesting that a participant fast for any laboratory evaluations.

          3. Is a healthy man or woman, aged 18 to 55 years, inclusive at the time of informed
             consent and first study medication dose for all cohorts will be included. Note that
             Cohort 12 will enroll healthy, elderly men and women, aged 65 to 75 years, inclusive.

          4. Weighs at least 50 kg and has a body mass index (BMI) from 18.0 to 35.0 kg/m^2,
             inclusive at Screening.

          5. A male participant who is nonsterilized and sexually active with a female partner of
             childbearing potential agrees to use adequate contraception from signing of informed
             consent throughout the duration of the study and for 12 weeks after last dose.

          6. A female participant with no childbearing potential, defined as the participant has
             been surgically sterilized (hysterectomy, bilateral oophorectomy or tubal ligation) or
             who are postmenopausal (defined as continuous amenorrhea of at least 2 y ears and
             follicle stimulating hormone (FSH) &gt;40 IU/L).

        Exclusion Criteria:

          1. Has received any investigational compound within 30 days prior to the first dose of
             study medication.

          2. Has received TAK-915 in a previous clinical study or as a therapeutic agent.

          3. Is an immediate family member, study site employee, or is in a dependent relationship
             with a study site employee who is involved in the conduct of this study (eg, spouse,
             parent, child, sibling) or may consent under duress.

          4. Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary,
             hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine disease,
             or psychiatric disorder, or other abnormality, which may impact the ability of the
             participant to participate or potentially confound the study results.

          5. Has a known hypersensitivity to any component of the formulation of TAK-915 and/or
             midazolam.

          6. If female, the participant is of childbearing potential (eg. premenopausal, not
             sterilized).

          7. Has a positive urine drug result for drugs of abuse at Screening or Check-in (Day 1).

          8. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
             abuse within 1 year prior to the Screening Visit or is unwilling to agree to abstain
             from alcohol and drugs throughout the study. One unit is equivalent to a half-pint of
             beer or 1 measure of spirits or 1 glass of wine.

          9. Has taken any excluded medication, supplements, or food products during the time
             periods listed in the Excluded Medications and Dietary Products table.

         10. Is pregnant or lactating or intending to become pregnant before, during, or within 12
             weeks after participating in this study ; or intending to donate ova during such time
             period.

         11. If male, the participant intends to donate sperm during the course of this study or
             for 12 weeks after the last dose of study medication.

         12. Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic
             disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy,
             asthma hypoxemia, hypertension, seizures, or allergic skin rash. There is any finding
             in the participant's medical history, physical examination, or safety laboratory tests
             giving reasonable suspicion of a disease that would contraindicate taking TAK-915, or
             a similar drug in the same class, or that might interfere with the conduct of the
             study. This includes, but is not limited to, peptic ulcer disease, seizure disorders,
             and cardiac arrhythmias.

         13. Has mental retardation or medical condition that can cause cognitive impairment.

         14. Has current or recent (within 6 months) gastrointestinal disease that would be
             expected to influence the absorption of drugs (ie, a history of malabsorption, any
             surgical intervention known to impact absorption [eg, bariatric surgery or bowel
             resection], esophageal reflux, peptic ulcer disease, erosive esophagitis, or frequent
             [more than once per week] occurrence of heartburn).

         15. Has a history of cancer, except basal cell carcinoma which has been in remission for
             at least 5 years prior to Check-in (Day -1).

         16. Has a positive test result for hepatitis B surface antigen (HBsAg), antibody to
             hepatitis C (anti -HCV) or a known history of human immunodeficiency virus infection
             at Screening.

         17. Has used nicotine-containing products (including but not limited to cigarettes, pipes,
             cigars, electronic cigarettes, chewing tobacco, nicotine patch or nicotine gum) within
             28 days prior to Check-in (Day -1). Cotinine test is positive at Screening or Check-in
             (Day -1).

         18. Has donated or lost 450 mL or more of his or her blood volume (including
             plasmapheresis), or had a transfusion of any blood product within 45 days prior the
             first dose of study medication.

         19. Has a Screening or Check-in (Day -1) abnormal (clinically significant)
             electrocardiogram (ECG). Entry of any participant with an abnormal (not clinically
             significant) ECG must be approved and documented by signature by the principal
             investigator.

         20. Has a supine blood pressure outside the ranges of 90 to 140 mmHg for systolic and 60
             to 90 mmHg for diastolic, confirmed on repeat testing within a maximum of 30 minutes,
             at the Screening Visit or Check-in (Day -1).

         21. Has a resting heart rate outside the range 40 to 100 bpm, confirmed on repeat testing
             within a maximum of 30 minutes, at the Screening Visit or Check-in (Day -1).

         22. Has a QT interval with Fridericia correction method (QTcF) &gt;430 ms (males) or &gt;450 ms
             (females) or PR outside the range 120 to 220 ms, confirmed on repeat testing within a
             maximum of 30 minutes, at the Screening Visit or Check-in (Day -1).

         23. Has abnormal Screening or Check-in (Day -1) laboratory values that suggest a
             clinically significant underlying disease or participant with the following lab
             abnormalities: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)
             &gt;1.5 the upper limits of normal.

         24. Has a risk of suicide according to the Investigator's clinical judgment (eg, per
             Columbia-Suicide Severity Rating Scale [C-SSRS] or has made a suicide attempt in the
             previous 6 months).

         25. Has poor peripheral venous access.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <results_first_submitted>February 1, 2018</results_first_submitted>
  <results_first_submitted_qc>October 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2019</results_first_posted>
  <last_update_submitted>October 4, 2018</last_update_submitted>
  <last_update_submitted_qc>October 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in the United States from 12 May 2015 01 Aug 2016.</recruitment_details>
      <pre_assignment_details>Healthy participants were enrolled to receive TAK-915 in any of the 5 parts of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SRD Cohorts Pooled Placebo</title>
          <description>TAK-915 placebo-matching suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>SRD Cohort 1 TAK-915 30 mg</title>
          <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>SRD Cohort 2: TAK-915 100 mg</title>
          <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>SRD Cohort 3: TAK-915 200 mg</title>
          <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>MRD Cohorts Pooled Placebo</title>
          <description>TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.</description>
        </group>
        <group group_id="P6">
          <title>MRD Cohort 5: TAK-915 30 mg</title>
          <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
        </group>
        <group group_id="P7">
          <title>MRD Cohort 6: TAK-915 100 mg</title>
          <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
        </group>
        <group group_id="P8">
          <title>MRD Cohort 7: TAK-915 200 mg</title>
          <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
        </group>
        <group group_id="P9">
          <title>DDI Cohort 8: TAK-915 + Midazolam 2 mg</title>
          <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).</description>
        </group>
        <group group_id="P10">
          <title>BA/FE Cohort 9 Group 1: A,B,C</title>
          <description>Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1, followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3. Each period was separated out by a 6 to 14-day washout period.</description>
        </group>
        <group group_id="P11">
          <title>BA/FE Cohort 10 Group 2: B,C,A</title>
          <description>Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1. Each period was separated out by a 6 to 14-day washout period.</description>
        </group>
        <group group_id="P12">
          <title>BA/FE Cohort 11 Group 3: C,A,B</title>
          <description>Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1 followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2. Each period was separated out by a 6 to 14-day washout period.</description>
        </group>
        <group group_id="P13">
          <title>ESSD Cohort 12: TAK-915 50 mg</title>
          <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SRD Cohorts Pooled Placebo</title>
          <description>TAK-915 placebo-matching suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>SRD Cohort 1 TAK-915 30 mg</title>
          <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>SRD Cohort 2: TAK-915 100 mg</title>
          <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>SRD Cohort 3: TAK-915 200 mg</title>
          <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>MRD Cohorts Pooled Placebo</title>
          <description>TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.</description>
        </group>
        <group group_id="B6">
          <title>MRD Cohort 5: TAK-915 30 mg</title>
          <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
        </group>
        <group group_id="B7">
          <title>MRD Cohort 6: TAK-915 100 mg</title>
          <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
        </group>
        <group group_id="B8">
          <title>MRD Cohort 7: TAK-915 200 mg</title>
          <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
        </group>
        <group group_id="B9">
          <title>DDI Cohort 8: TAK-915 + Midazolam 2 mg</title>
          <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).</description>
        </group>
        <group group_id="B10">
          <title>BA/FE Cohort 9 Group 1: A,B,C</title>
          <description>Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1, followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3. Each period was separated out by a 6 to 14-day washout period.</description>
        </group>
        <group group_id="B11">
          <title>BA/FE Cohort 10 Group 2: B,C,A</title>
          <description>Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1. Each period was separated out by a 6 to 14-day washout period.</description>
        </group>
        <group group_id="B12">
          <title>BA/FE Cohort 11 Group 3: C,A,B</title>
          <description>Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1 followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2. Each period was separated out by a 6 to 14-day washout period.</description>
        </group>
        <group group_id="B13">
          <title>ESSD Cohort 12: TAK-915 50 mg</title>
          <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
        </group>
        <group group_id="B14">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="12"/>
            <count group_id="B10" value="4"/>
            <count group_id="B11" value="4"/>
            <count group_id="B12" value="4"/>
            <count group_id="B13" value="8"/>
            <count group_id="B14" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" spread="9.76" lower_limit="25" upper_limit="52"/>
                    <measurement group_id="B2" value="37.8" spread="16.68" lower_limit="18" upper_limit="55"/>
                    <measurement group_id="B3" value="41.0" spread="12.47" lower_limit="23" upper_limit="55"/>
                    <measurement group_id="B4" value="31.9" spread="6.76" lower_limit="24" upper_limit="45"/>
                    <measurement group_id="B5" value="35.7" spread="11.36" lower_limit="23" upper_limit="52"/>
                    <measurement group_id="B6" value="33.7" spread="4.32" lower_limit="27" upper_limit="40"/>
                    <measurement group_id="B7" value="37.8" spread="5.74" lower_limit="34" upper_limit="49"/>
                    <measurement group_id="B8" value="38.7" spread="10.03" lower_limit="22" upper_limit="52"/>
                    <measurement group_id="B9" value="38.5" spread="8.53" lower_limit="23" upper_limit="51"/>
                    <measurement group_id="B10" value="35.3" spread="14.36" lower_limit="18" upper_limit="52"/>
                    <measurement group_id="B11" value="37.5" spread="12.34" lower_limit="26" upper_limit="55"/>
                    <measurement group_id="B12" value="37.5" spread="8.70" lower_limit="29" upper_limit="49"/>
                    <measurement group_id="B13" value="68.8" spread="2.25" lower_limit="65" upper_limit="72"/>
                    <measurement group_id="B14" value="39.177" lower_limit="18" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="4.41" lower_limit="22" upper_limit="33"/>
                    <measurement group_id="B2" value="24.9" spread="5.26" lower_limit="19" upper_limit="31"/>
                    <measurement group_id="B3" value="26.1" spread="2.95" lower_limit="23" upper_limit="30"/>
                    <measurement group_id="B4" value="27.6" spread="3.99" lower_limit="22" upper_limit="33"/>
                    <measurement group_id="B5" value="27.4" spread="1.71" lower_limit="26" upper_limit="30"/>
                    <measurement group_id="B6" value="26.5" spread="3.00" lower_limit="23" upper_limit="30"/>
                    <measurement group_id="B7" value="24.4" spread="3.95" lower_limit="19" upper_limit="30"/>
                    <measurement group_id="B8" value="27.9" spread="2.52" lower_limit="25" upper_limit="32"/>
                    <measurement group_id="B9" value="28.2" spread="2.23" lower_limit="24" upper_limit="31"/>
                    <measurement group_id="B10" value="27.7" spread="6.33" lower_limit="19" upper_limit="33"/>
                    <measurement group_id="B11" value="27.0" spread="1.52" lower_limit="26" upper_limit="29"/>
                    <measurement group_id="B12" value="30.6" spread="2.93" lower_limit="27" upper_limit="33"/>
                    <measurement group_id="B13" value="28.2" spread="2.75" lower_limit="24" upper_limit="34"/>
                    <measurement group_id="B14" value="27.238" lower_limit="19" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Particiapnt has never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="7"/>
                    <measurement group_id="B14" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Particiapnt is a current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant is an ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Xanthine/caffeine history</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="7"/>
                    <measurement group_id="B14" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.</description>
        <time_frame>Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)</time_frame>
        <population>Safety set included all participants who were enrolled and received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohorts Pooled Placebo</title>
            <description>TAK-915 placebo-matching suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohorts Pooled Placebo</title>
            <description>TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O8">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O9">
            <title>DDI Cohort 8: Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Days 1 and 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
          <group group_id="O10">
            <title>DDI Cohort 8: TAK-915 100 mg</title>
            <description>TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16.</description>
          </group>
          <group group_id="O11">
            <title>DDI Cohort 8: TAK-915 + Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
          <group group_id="O12">
            <title>BA/FE Cohort Regimen A</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of ant period.</description>
          </group>
          <group group_id="O13">
            <title>BA/FE Cohort Regimen B</title>
            <description>TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of any Period.</description>
          </group>
          <group group_id="O14">
            <title>BA/FE Cohort Regimen C</title>
            <description>TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of any period.</description>
          </group>
          <group group_id="O15">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.</description>
          <population>Safety set included all participants who were enrolled and received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="33.3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="41.7"/>
                    <measurement group_id="O11" value="8.3"/>
                    <measurement group_id="O12" value="16.7"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="25"/>
                    <measurement group_id="O15" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Markedly Abnormal Safety Laboratory Tests</title>
        <description>The percentage of participants with any markedly abnormal standard safety laboratory values, including haematology, serum chemistries, or urinalysis, during the treatment period.</description>
        <time_frame>Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)</time_frame>
        <population>Safety set included all participants who were enrolled and received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohorts Pooled Placebo</title>
            <description>TAK-915 placebo-matching suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohorts Pooled Placebo</title>
            <description>TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O8">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O9">
            <title>DDI Cohort 8: Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Days 1 and 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
          <group group_id="O10">
            <title>DDI Cohort 8: TAK-915 100 mg</title>
            <description>TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16.</description>
          </group>
          <group group_id="O11">
            <title>DDI Cohort 8: TAK-915 + Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
          <group group_id="O12">
            <title>BA/FE Cohort Regimen A</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of ant period.</description>
          </group>
          <group group_id="O13">
            <title>BA/FE Cohort Regimen B</title>
            <description>TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of any Period.</description>
          </group>
          <group group_id="O14">
            <title>BA/FE Cohort Regimen C</title>
            <description>TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of any period.</description>
          </group>
          <group group_id="O15">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Markedly Abnormal Safety Laboratory Tests</title>
          <description>The percentage of participants with any markedly abnormal standard safety laboratory values, including haematology, serum chemistries, or urinalysis, during the treatment period.</description>
          <population>Safety set included all participants who were enrolled and received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Markedly Abnormal Vital Sign Measurements</title>
        <description>The percentage of participants who meet markedly abnormal criteria for vital signs after dosing, including oral body temperature (temp.), respiration rate, pulse rate (PR) Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) for assessment in positions of supine or standing. Vital signs were considered abnormal if they were beyond the values defined in categories.</description>
        <time_frame>Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)</time_frame>
        <population>Safety set included all participants who were enrolled and received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohorts Pooled Placebo</title>
            <description>TAK-915 placebo-matching suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohorts Pooled Placebo</title>
            <description>TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O8">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O9">
            <title>DDI Cohort 8: Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Days 1 and 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
          <group group_id="O10">
            <title>DDI Cohort 8: TAK-915 100 mg</title>
            <description>TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16.</description>
          </group>
          <group group_id="O11">
            <title>DDI Cohort 8: TAK-915 + Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
          <group group_id="O12">
            <title>BA/FE Cohort Regimen A</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of any period.</description>
          </group>
          <group group_id="O13">
            <title>BA/FE Cohort Regimen B</title>
            <description>TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of any Period.</description>
          </group>
          <group group_id="O14">
            <title>BA/FE Cohort Regimen C</title>
            <description>TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of any period.</description>
          </group>
          <group group_id="O15">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Markedly Abnormal Vital Sign Measurements</title>
          <description>The percentage of participants who meet markedly abnormal criteria for vital signs after dosing, including oral body temperature (temp.), respiration rate, pulse rate (PR) Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) for assessment in positions of supine or standing. Vital signs were considered abnormal if they were beyond the values defined in categories.</description>
          <population>Safety set included all participants who were enrolled and received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Standing, after 1 minute SBP, &lt;85 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="16.7"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="8.3"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 1 minutes SBP, &gt;180 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 3 minutes SBP(mmHg), &lt;85 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8.3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 3 minutes SBP, &gt;180 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="16.7"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine, after 5 minutes SBP, &lt;85 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="16.7"/>
                    <measurement group_id="O13" value="8.3"/>
                    <measurement group_id="O14" value="8.3"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine, after 5 minutes SBP, &gt;180 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 1 minute DBP, &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="8.3"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 1 minute DBP, &gt;110 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 3 minutes DBP, &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="8.3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 3 minutes DBP, &gt;110 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine, after 5 minutes DBP, &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="8.3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="8.3"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="8.3"/>
                    <measurement group_id="O12" value="8.3"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine, after 5 minutes DBP, &gt;110 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 1 min PR, &lt;50 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 1 min PR, &gt;120 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="33.3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="8.3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="8.3"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 3 mins PR, &lt;50 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="8.3"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 3 mins PR, &gt;120 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="16.7"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="8.3"/>
                    <measurement group_id="O11" value="8.3"/>
                    <measurement group_id="O12" value="8.3"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine, after 5 mins PR, &lt;50 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="50"/>
                    <measurement group_id="O7" value="50"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine, after 5 mins PR, &gt;120 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 1 min Temperature, &lt;35.6 Â°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 1 min Temperature, &gt;37.7 Â°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 3 mins Temperature, &lt;35.6 Â°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, after 3 mins Temperature, &gt;37.7 Â°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine, after 5 mins Temperature, &lt;35.6 Â°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="16.7"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="8.3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="8.3"/>
                    <measurement group_id="O15" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine, after 5 mins Temperature, &gt;37.7 Â°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Markedly Abnormal Values of 12-Lead Electrocardiogram (ECG) Parameters</title>
        <description>The percentage of participants who meet markedly abnormal criteria for ECG parameters as specified by the protocol and statistical analysis plan during the treatment period. ECG parameters were considered abnormal if they were beyond the values defined in categories.</description>
        <time_frame>Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)</time_frame>
        <population>Safety set included all participants who were enrolled and received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohorts Pooled Placebo</title>
            <description>TAK-915 placebo-matching suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohorts Pooled Placebo</title>
            <description>TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O8">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O9">
            <title>DDI Cohort 8: Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Days 1 and 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
          <group group_id="O10">
            <title>DDI Cohort 8: TAK-915 100 mg</title>
            <description>TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16.</description>
          </group>
          <group group_id="O11">
            <title>DDI Cohort 8: TAK-915 + Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
          <group group_id="O12">
            <title>BA/FE Cohort Regimen A</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of ant period.</description>
          </group>
          <group group_id="O13">
            <title>BA/FE Cohort Regimen B</title>
            <description>TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of any Period.</description>
          </group>
          <group group_id="O14">
            <title>BA/FE Cohort Regimen C</title>
            <description>TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of any period.</description>
          </group>
          <group group_id="O15">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Markedly Abnormal Values of 12-Lead Electrocardiogram (ECG) Parameters</title>
          <description>The percentage of participants who meet markedly abnormal criteria for ECG parameters as specified by the protocol and statistical analysis plan during the treatment period. ECG parameters were considered abnormal if they were beyond the values defined in categories.</description>
          <population>Safety set included all participants who were enrolled and received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate, &lt;50 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="50"/>
                    <measurement group_id="O7" value="50"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="8.3"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate, &gt;120 beats/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval, &lt;=80 msec (ms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval, &gt;=200 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8.3"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="33.3"/>
                    <measurement group_id="O9" value="8.3"/>
                    <measurement group_id="O10" value="8.3"/>
                    <measurement group_id="O11" value="16.7"/>
                    <measurement group_id="O12" value="25"/>
                    <measurement group_id="O13" value="25"/>
                    <measurement group_id="O14" value="8.3"/>
                    <measurement group_id="O15" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval, &lt;=80 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="8.3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="33.3"/>
                    <measurement group_id="O9" value="8.3"/>
                    <measurement group_id="O10" value="25.0"/>
                    <measurement group_id="O11" value="25.0"/>
                    <measurement group_id="O12" value="16.7"/>
                    <measurement group_id="O13" value="16.7"/>
                    <measurement group_id="O14" value="8.3"/>
                    <measurement group_id="O15" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval, &gt;=180 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval, &lt;=300 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval, &gt;=460 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval, &lt;=300 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval,â‰¥500ms OR â‰¥450ms and â‰¥30ms CFB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="16.7"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="8.3"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval, &lt;= 300 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval, â‰¥500 msec OR â‰¥ 450 msec and â‰¥30 CFB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-915</title>
        <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 4: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally via syringe, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O8">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-915</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.750" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O2" value="2.000" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O3" value="2.000" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="2.508" lower_limit="1.00" upper_limit="6.10"/>
                    <measurement group_id="O5" value="1.500" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O6" value="1.500" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O7" value="3.058" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O8" value="1.500" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="1.500" lower_limit="1.50" upper_limit="2.00"/>
                    <measurement group_id="O6" value="2.000" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O7" value="2.00" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="1.500" lower_limit="1.50" upper_limit="1.52"/>
                    <measurement group_id="O6" value="2.500" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O7" value="3.000" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-915</title>
        <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 4: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally via syringe, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O8">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-915</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.7" spread="42.77" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O2" value="654.8" spread="145.97" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O3" value="417.3" spread="96.27" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="675.8" spread="168.66" lower_limit="1.00" upper_limit="6.10"/>
                    <measurement group_id="O5" value="209.5" spread="46.60" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O6" value="651.8" spread="227.77" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O7" value="743.8" spread="148.45" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O8" value="414.0" spread="106.43" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="196.0" spread="47.72" lower_limit="1.50" upper_limit="2.00"/>
                    <measurement group_id="O6" value="651.0" spread="130.51" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O7" value="836.7" spread="220.01" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O8" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="397.5" spread="137.14" lower_limit="1.50" upper_limit="1.52"/>
                    <measurement group_id="O6" value="1081.0" spread="170.94" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O7" value="1865.0" spread="334.71" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O8" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-915</title>
        <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 4: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally via syringe, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O8">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-915</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2560.0" spread="631.76" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O2" value="8293.3" spread="1430.62" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O3" value="5478.1" spread="729.80" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="10285.1" spread="1515.01" lower_limit="1.00" upper_limit="6.10"/>
                    <measurement group_id="O5" value="2610.0" spread="534.55" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O6" value="7984.6" spread="1437.41" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O7" value="11640.5" spread="1889.06" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O8" value="4693.0" spread="637.27" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="2301.7" spread="782.55" lower_limit="1.50" upper_limit="2.00"/>
                    <measurement group_id="O6" value="8333.9" spread="890.57" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O7" value="12549.3" spread="3355.02" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O8" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="5688.9" spread="2759.15" lower_limit="1.50" upper_limit="1.52"/>
                    <measurement group_id="O6" value="15068.7" spread="2367.02" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O7" value="31656.0" spread="5574.82" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O8" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-915</title>
        <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 4: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally via syringe, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O8">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-915</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5187.3" spread="956.99"/>
                    <measurement group_id="O2" value="18229.5" spread="5124.97"/>
                    <measurement group_id="O3" value="10812.4" spread="1098.50"/>
                    <measurement group_id="O4" value="24204.7" spread="3870.08"/>
                    <measurement group_id="O5" value="5380.9" spread="2065.75"/>
                    <measurement group_id="O6" value="15640.0" spread="2998.50"/>
                    <measurement group_id="O7" value="30251.6" spread="4473.58"/>
                    <measurement group_id="O8" value="11552.2" spread="2214.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="2301.7" spread="782.55"/>
                    <measurement group_id="O6" value="8334.6" spread="890.88"/>
                    <measurement group_id="O7" value="12549.3" spread="3355.02"/>
                    <measurement group_id="O8" value="NA" spread="NA">Data was not analysed for this arm group at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="12653.2" spread="8536.11"/>
                    <measurement group_id="O6" value="27924.7" spread="7330.59"/>
                    <measurement group_id="O7" value="67706.4" spread="22451.23"/>
                    <measurement group_id="O8" value="NA" spread="NA">Data was not analysed for this arm group at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCâˆž: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-915</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 4: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally via syringe, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O8">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCâˆž: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-915</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6197.1" spread="1102.70" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O2" value="19345.6" spread="5548.95" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O3" value="12198.3" spread="1312.58" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="30243.3" spread="7208.93" lower_limit="1.00" upper_limit="6.10"/>
                    <measurement group_id="O5" value="6565.6" spread="3237.81" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O6" value="17507.2" spread="4461.40" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O7" value="40326.7" spread="11260.16" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O8" value="16991.5" spread="4349.17" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rac(AUC): Accumulation Ratios Between Day 14 AUC(0-24) and Day 1 AUC(0-24) for TAK-915</title>
        <time_frame>Days 1 and 14 pre-dose and at multiple time points (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O2">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O3">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Rac(AUC): Accumulation Ratios Between Day 14 AUC(0-24) and Day 1 AUC(0-24) for TAK-915</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.100" spread="0.6568"/>
                    <measurement group_id="O2" value="1.973" spread="0.6523"/>
                    <measurement group_id="O3" value="2.761" spread="0.5207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rac(Cmax): Accumulation Ratios Between Day 14 Cmax and Day 1 Cmax for TAK-915</title>
        <time_frame>Days 1 and 14 pre-dose and at multiple time points (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O2">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O3">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Rac(Cmax): Accumulation Ratios Between Day 14 Cmax and Day 1 Cmax for TAK-915</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.884" spread="0.4627"/>
                    <measurement group_id="O2" value="1.859" spread="0.7642"/>
                    <measurement group_id="O3" value="2.556" spread="0.5148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time Dependency Assessment From AUC(0-24) After Last Dose for TAK-915 on Day 14 in MRD Cohorts Compared to AUC(0-inf) After a Single Dose on Day 1</title>
        <time_frame>Days 1 and 14 pre-dose and at multiple time points (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O2">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O3">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Dependency Assessment From AUC(0-24) After Last Dose for TAK-915 on Day 14 in MRD Cohorts Compared to AUC(0-inf) After a Single Dose on Day 1</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.873" spread="0.1342"/>
                    <measurement group_id="O2" value="0.883" spread="0.1441"/>
                    <measurement group_id="O3" value="0.846" spread="0.1463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for Midazolam Alone (Day 1) and in the Presence of TAK-915 (Day 16) in DDI Cohort</title>
        <time_frame>Days 1 and 16 pre-dose and at multiple timepoints (up to 24 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>DDI Cohort 7: TAK-915 + Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for Midazolam Alone (Day 1) and in the Presence of TAK-915 (Day 16) in DDI Cohort</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for Midazolam Alone (Day 1) and in the Presence of TAK-915 (Day 16) in DDI Cohort</title>
        <time_frame>Days 1 and 16 pre-dose and at multiple timepoints (up to 24 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>DDI Cohort 7: TAK-915 + Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for Midazolam Alone (Day 1) and in the Presence of TAK-915 (Day 16) in DDI Cohort</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="5.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24) for Midazolam After Single Dose (Day 1)/AUC(0-24) for Midazolam After 7 Daily Doses of TAK-915 (Day 16) in DDI Cohort</title>
        <time_frame>Days 1 and 16 pre-dose and at multiple timepoints (up to 24 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>DDI Cohort 7: TAK-915 + Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24) for Midazolam After Single Dose (Day 1)/AUC(0-24) for Midazolam After 7 Daily Doses of TAK-915 (Day 16) in DDI Cohort</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.735" spread="0.1509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (t1/2) for TAK-915</title>
        <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 4: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally via syringe, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O8">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (t1/2) for TAK-915</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.246" spread="42.77" lower_limit="22.74" upper_limit="55.60"/>
                    <measurement group_id="O2" value="34.008" spread="145.97" lower_limit="27.05" upper_limit="85.65"/>
                    <measurement group_id="O3" value="32.621" spread="96.27" lower_limit="23.02" upper_limit="39.02"/>
                    <measurement group_id="O4" value="37.826" spread="168.66" lower_limit="29.50" upper_limit="55.78"/>
                    <measurement group_id="O5" value="37.166" spread="46.60" lower_limit="20.08" upper_limit="50.02"/>
                    <measurement group_id="O6" value="23.326" spread="227.77" lower_limit="18.77" upper_limit="46.44"/>
                    <measurement group_id="O7" value="46.408" spread="148.45" lower_limit="24.33" upper_limit="78.31"/>
                    <measurement group_id="O8" value="61.244" spread="106.43" lower_limit="27.71" upper_limit="75.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="32.770" spread="137.14" lower_limit="22.97" upper_limit="61.40"/>
                    <measurement group_id="O6" value="23.517" spread="170.94" lower_limit="17.57" upper_limit="28.73"/>
                    <measurement group_id="O7" value="35.503" spread="334.71" lower_limit="24.75" upper_limit="54.51"/>
                    <measurement group_id="O8" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F: Apparent Clearance for TAK-915</title>
        <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam. Number of participants analysed is the participants who were evaluable in each cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 4: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally via syringe, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O8">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F: Apparent Clearance for TAK-915</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam. Number of participants analysed is the participants who were evaluable in each cohort.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.966" spread="0.8498" lower_limit="22.74" upper_limit="55.60"/>
                    <measurement group_id="O2" value="5.565" spread="1.7418" lower_limit="27.05" upper_limit="85.65"/>
                    <measurement group_id="O3" value="16.566" spread="1.9026" lower_limit="23.02" upper_limit="39.02"/>
                    <measurement group_id="O4" value="6.928" spread="1.5930" lower_limit="29.50" upper_limit="55.78"/>
                    <measurement group_id="O5" value="5.437" spread="2.3306" lower_limit="20.08" upper_limit="50.02"/>
                    <measurement group_id="O6" value="5.993" spread="1.3303" lower_limit="18.77" upper_limit="46.44"/>
                    <measurement group_id="O7" value="5.313" spread="1.6232" lower_limit="24.33" upper_limit="78.31"/>
                    <measurement group_id="O8" value="5.651" spread="2.3825" lower_limit="27.71" upper_limit="75.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="6.289" spread="2.6024" lower_limit="22.97" upper_limit="61.40"/>
                    <measurement group_id="O6" value="6.791" spread="1.1948" lower_limit="17.57" upper_limit="28.73"/>
                    <measurement group_id="O7" value="6.625" spread="1.2982" lower_limit="24.75" upper_limit="54.51"/>
                    <measurement group_id="O8" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) for TAK-915</title>
        <time_frame>SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 4: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally via syringe, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O8">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) for TAK-915</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271.621" spread="81.4842" lower_limit="22.74" upper_limit="55.60"/>
                    <measurement group_id="O2" value="253.274" spread="44.1565" lower_limit="27.05" upper_limit="85.65"/>
                    <measurement group_id="O3" value="739.900" spread="138.9342" lower_limit="23.02" upper_limit="39.02"/>
                    <measurement group_id="O4" value="384.373" spread="54.7107" lower_limit="29.50" upper_limit="55.78"/>
                    <measurement group_id="O5" value="253.191" spread="43.9653" lower_limit="20.08" upper_limit="50.02"/>
                    <measurement group_id="O6" value="219.807" spread="44.0421" lower_limit="18.77" upper_limit="46.44"/>
                    <measurement group_id="O7" value="289.052" spread="33.6825" lower_limit="24.33" upper_limit="78.31"/>
                    <measurement group_id="O8" value="251.206" spread="28.7250" lower_limit="27.71" upper_limit="75.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="290.034" spread="47.4883" lower_limit="22.97" upper_limit="61.40"/>
                    <measurement group_id="O6" value="231.463" spread="38.5789" lower_limit="17.57" upper_limit="28.73"/>
                    <measurement group_id="O7" value="373.816" spread="143.239" lower_limit="24.75" upper_limit="54.51"/>
                    <measurement group_id="O8" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Drug Excreted in Urine (Ae) for TAK-915</title>
        <time_frame>SRD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 4: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally via syringe, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Drug Excreted in Urine (Ae) for TAK-915</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ng</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10716.238" spread="6732.8265" lower_limit="22.74" upper_limit="55.60"/>
                    <measurement group_id="O2" value="56307.372" spread="22847.5616" lower_limit="27.05" upper_limit="85.65"/>
                    <measurement group_id="O3" value="39016.323" spread="39432.2098" lower_limit="23.02" upper_limit="39.02"/>
                    <measurement group_id="O4" value="70789.157" spread="31812.6780" lower_limit="29.50" upper_limit="55.78"/>
                    <measurement group_id="O5" value="11637.538" spread="7559.7833" lower_limit="20.08" upper_limit="50.02"/>
                    <measurement group_id="O6" value="75873.405" spread="57990.3620" lower_limit="18.77" upper_limit="46.44"/>
                    <measurement group_id="O7" value="84953.950" spread="28044.2529" lower_limit="24.33" upper_limit="78.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="23712.223" spread="16960.3220" lower_limit="22.97" upper_limit="61.40"/>
                    <measurement group_id="O6" value="107635.360" spread="66665.1502" lower_limit="17.57" upper_limit="28.73"/>
                    <measurement group_id="O7" value="173279.223" spread="102551.0702" lower_limit="24.75" upper_limit="54.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction of Drug Excreted in Urine (Fe) for TAK-915</title>
        <time_frame>SRD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 4: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally via syringe, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Drug Excreted in Urine (Fe) for TAK-915</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>fraction excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.0224" lower_limit="22.74" upper_limit="55.60"/>
                    <measurement group_id="O2" value="0.056" spread="0.0228" lower_limit="27.05" upper_limit="85.65"/>
                    <measurement group_id="O3" value="0.020" spread="0.0197" lower_limit="23.02" upper_limit="39.02"/>
                    <measurement group_id="O4" value="0.035" spread="0.0159" lower_limit="29.50" upper_limit="55.78"/>
                    <measurement group_id="O5" value="0.039" spread="0.0252" lower_limit="20.08" upper_limit="50.02"/>
                    <measurement group_id="O6" value="0.076" spread="0.0580" lower_limit="18.77" upper_limit="46.44"/>
                    <measurement group_id="O7" value="0.042" spread="0.0140" lower_limit="24.33" upper_limit="78.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="0.079" spread="0.0565" lower_limit="22.97" upper_limit="61.40"/>
                    <measurement group_id="O6" value="0.108" spread="0.0667" lower_limit="17.57" upper_limit="28.73"/>
                    <measurement group_id="O7" value="0.099" spread="0.0471" lower_limit="24.75" upper_limit="54.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance (CLr) for TAK-915</title>
        <time_frame>SRD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 4: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally via syringe, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr) for TAK-915</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.140" spread="1.3783" lower_limit="22.74" upper_limit="55.60"/>
                    <measurement group_id="O2" value="3.191" spread="1.1645" lower_limit="27.05" upper_limit="85.65"/>
                    <measurement group_id="O3" value="3.612" spread="3.5780" lower_limit="23.02" upper_limit="39.02"/>
                    <measurement group_id="O4" value="2.915" spread="1.3632" lower_limit="29.50" upper_limit="55.78"/>
                    <measurement group_id="O5" value="2.265" spread="1.7248" lower_limit="20.08" upper_limit="50.02"/>
                    <measurement group_id="O6" value="5.047" spread="4.2166" lower_limit="18.77" upper_limit="46.44"/>
                    <measurement group_id="O7" value="2.934" spread="1.2499" lower_limit="24.33" upper_limit="78.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="2.208" spread="0.8706" lower_limit="22.97" upper_limit="61.40"/>
                    <measurement group_id="O6" value="4.696" spread="4.5467" lower_limit="17.57" upper_limit="28.73"/>
                    <measurement group_id="O7" value="3.246" spread="2.0065" lower_limit="24.75" upper_limit="54.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-915 on Day 1 in DDI Cohort</title>
        <time_frame>Days 1 at multiple time points (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>DDI Cohort 7: TAK-915 + Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-915 on Day 1 in DDI Cohort</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="519.7" spread="156.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-915 on Day 1 in DDI Cohort</title>
        <time_frame>Days 1 at multiple time points (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>DDI Cohort 7: TAK-915 + Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-915 on Day 1 in DDI Cohort</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7324.5" spread="2130.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-tau): Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau Over a Dosing Interval Where Tau is the Length of the Dosing Interval for TAK-915 in DDI Cohort</title>
        <time_frame>Days 16 at multiple time points (up to 96 hours) post dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>DDI Cohort 7: TAK-915 + Midazolam 2 mg</title>
            <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tau): Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau Over a Dosing Interval Where Tau is the Length of the Dosing Interval for TAK-915 in DDI Cohort</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17093.9" spread="5803.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of TAK-915 Metabolite Cmax to TAK-915 Cmax in SRD and MRD Cohorts</title>
        <time_frame>Day 1 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 4: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally via syringe, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O6">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O7">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O8">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of TAK-915 Metabolite Cmax to TAK-915 Cmax in SRD and MRD Cohorts</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.230" spread="0.0281" lower_limit="22.74" upper_limit="55.60"/>
                    <measurement group_id="O2" value="0.248" spread="0.0440" lower_limit="27.05" upper_limit="85.65"/>
                    <measurement group_id="O3" value="0.254" spread="0.0287" lower_limit="23.02" upper_limit="39.02"/>
                    <measurement group_id="O4" value="0.273" spread="0.0550" lower_limit="29.50" upper_limit="55.78"/>
                    <measurement group_id="O5" value="0.212" spread="0.0410" lower_limit="20.08" upper_limit="50.02"/>
                    <measurement group_id="O6" value="0.267" spread="0.0454" lower_limit="18.77" upper_limit="46.44"/>
                    <measurement group_id="O7" value="0.277" spread="0.0632" lower_limit="24.33" upper_limit="78.31"/>
                    <measurement group_id="O8" value="0.207" spread="0.0326" lower_limit="27.71" upper_limit="75.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                    <measurement group_id="O5" value="0.356" spread="0.0609" lower_limit="22.97" upper_limit="61.40"/>
                    <measurement group_id="O6" value="0.480" spread="0.0764" lower_limit="17.57" upper_limit="28.73"/>
                    <measurement group_id="O7" value="0.0764" spread="0.0690" lower_limit="24.75" upper_limit="54.51"/>
                    <measurement group_id="O8" value="NA" spread="NA" lower_limit="NA" upper_limit="NA">Data was not analysed for this arm group at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of TAK-915 Metabolite AUC(0-inf) to TAK-915 AUC(0-inf) in SRD Cohorts</title>
        <time_frame>Day 1 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>SRD Cohort 1 TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>SRD Cohort 2: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>SRD Cohort 3: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>SRD Cohort 4: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally via syringe, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>ESSD Cohort 12: TAK-915 50 mg</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of TAK-915 Metabolite AUC(0-inf) to TAK-915 AUC(0-inf) in SRD Cohorts</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.492" spread="0.1179" lower_limit="22.74" upper_limit="55.60"/>
                    <measurement group_id="O2" value="0.475" spread="0.1029" lower_limit="27.05" upper_limit="85.65"/>
                    <measurement group_id="O3" value="0.483" spread="0.1037" lower_limit="23.02" upper_limit="39.02"/>
                    <measurement group_id="O4" value="0.576" spread="0.1071" lower_limit="29.50" upper_limit="55.78"/>
                    <measurement group_id="O5" value="0.451" spread="0.1334" lower_limit="27.71" upper_limit="75.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of TAK-915 Metabolite Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau Over a Dosing Interval [AUC(0-tau)] Where Tau is the Length of the Dosing Interval to TAK-915 AUC(0-tau) in MRD Cohorts</title>
        <time_frame>Day 14 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>MRD Cohort 5: TAK-915 30 mg</title>
            <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O2">
            <title>MRD Cohort 6: TAK-915 100 mg</title>
            <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
          <group group_id="O3">
            <title>MRD Cohort 7: TAK-915 200 mg</title>
            <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of TAK-915 Metabolite Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau Over a Dosing Interval [AUC(0-tau)] Where Tau is the Length of the Dosing Interval to TAK-915 AUC(0-tau) in MRD Cohorts</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.496" spread="0.1177" lower_limit="20.08" upper_limit="50.02"/>
                    <measurement group_id="O2" value="0.640" spread="0.1177" lower_limit="18.77" upper_limit="46.44"/>
                    <measurement group_id="O3" value="0.505" spread="0.0940" lower_limit="24.33" upper_limit="78.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</title>
        <time_frame>Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>BA/FE Cohort Regimen A</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of ant period.</description>
          </group>
          <group group_id="O2">
            <title>BA/FE Cohort Regimen B</title>
            <description>TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of any Period.</description>
          </group>
          <group group_id="O3">
            <title>BA/FE Cohort Regimen C</title>
            <description>TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of any period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-915</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337.0" spread="337.0"/>
                    <measurement group_id="O2" value="208.0" spread="68.48"/>
                    <measurement group_id="O3" value="143.4" spread="55.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="18.55"/>
                    <measurement group_id="O2" value="48.9" spread="13.21"/>
                    <measurement group_id="O3" value="34.6" spread="16.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</title>
        <time_frame>Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>BA/FE Cohort Regimen A</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of ant period.</description>
          </group>
          <group group_id="O2">
            <title>BA/FE Cohort Regimen B</title>
            <description>TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of any Period.</description>
          </group>
          <group group_id="O3">
            <title>BA/FE Cohort Regimen C</title>
            <description>TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of any period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-915</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8412.3" spread="2019.40"/>
                    <measurement group_id="O2" value="7310.0" spread="1928.95"/>
                    <measurement group_id="O3" value="5740.2" spread="2227.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3785.3" spread="771.24"/>
                    <measurement group_id="O2" value="2992.1" spread="582.21"/>
                    <measurement group_id="O3" value="2208.7" spread="888.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</title>
        <time_frame>Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>BA/FE Cohort Regimen A</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of ant period.</description>
          </group>
          <group group_id="O2">
            <title>BA/FE Cohort Regimen B</title>
            <description>TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of any Period.</description>
          </group>
          <group group_id="O3">
            <title>BA/FE Cohort Regimen C</title>
            <description>TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of any period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-915</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10155.2" spread="2909.10"/>
                    <measurement group_id="O2" value="9414.5" spread="9414.5"/>
                    <measurement group_id="O3" value="7151.5" spread="2836.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4727.2" spread="1073.11"/>
                    <measurement group_id="O2" value="4145.2" spread="1027.33"/>
                    <measurement group_id="O3" value="3011.6" spread="1315.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</title>
        <time_frame>Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>BA/FE Cohort Regimen A</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of ant period.</description>
          </group>
          <group group_id="O2">
            <title>BA/FE Cohort Regimen B</title>
            <description>TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of any Period.</description>
          </group>
          <group group_id="O3">
            <title>BA/FE Cohort Regimen C</title>
            <description>TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of any period.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-915</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="1.00" upper_limit="3.40"/>
                    <measurement group_id="O2" value="3.000" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O3" value="7.000" lower_limit="4.08" upper_limit="24.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.250" lower_limit="1.00" upper_limit="12.00"/>
                    <measurement group_id="O2" value="10.000" lower_limit="2.00" upper_limit="24.00"/>
                    <measurement group_id="O3" value="24.000" lower_limit="10.00" upper_limit="32.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (t1/2) for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</title>
        <time_frame>Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>BA/FE Cohort Regimen A</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of ant period.</description>
          </group>
          <group group_id="O2">
            <title>BA/FE Cohort Regimen B</title>
            <description>TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of any Period.</description>
          </group>
          <group group_id="O3">
            <title>BA/FE Cohort Regimen C</title>
            <description>TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of any period.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (t1/2) for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-915</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.973" lower_limit="19.83" upper_limit="52.65"/>
                    <measurement group_id="O2" value="45.359" lower_limit="21.43" upper_limit="63.71"/>
                    <measurement group_id="O3" value="40.101" lower_limit="19.46" upper_limit="53.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.937" lower_limit="19.68" upper_limit="68.78"/>
                    <measurement group_id="O2" value="50.010" lower_limit="19.55" upper_limit="142.18"/>
                    <measurement group_id="O3" value="48.406" lower_limit="19.43" upper_limit="76.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Î»z: Terminal Elimination Rate Constant for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</title>
        <time_frame>Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose</time_frame>
        <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
        <group_list>
          <group group_id="O1">
            <title>BA/FE Cohort Regimen A</title>
            <description>TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of ant period.</description>
          </group>
          <group group_id="O2">
            <title>BA/FE Cohort Regimen B</title>
            <description>TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of any Period.</description>
          </group>
          <group group_id="O3">
            <title>BA/FE Cohort Regimen C</title>
            <description>TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of any period.</description>
          </group>
        </group_list>
        <measure>
          <title>Î»z: Terminal Elimination Rate Constant for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort</title>
          <population>Pharmacokinetic set included all participants who received study drug and have at least 1 measurable plasma concentration or amount of drug in the urine for either TAK-915 or its metabolite M-I or for midazolam or its metabolite 1-hydroxymidazolam.</population>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-915</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0202" spread="0.00623"/>
                    <measurement group_id="O2" value="0.0187" spread="0.00677"/>
                    <measurement group_id="O3" value="0.0202" spread="0.00702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0180" spread="0.00665"/>
                    <measurement group_id="O2" value="0.0155" spread="0.00834"/>
                    <measurement group_id="O3" value="0.0162" spread="0.00748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment. Adverse events were summarized as per the regimen received by the participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>SRD Cohorts Pooled Placebo</title>
          <description>TAK-915 placebo-matching suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>SRD Cohort 1 TAK-915 30 mg</title>
          <description>TAK-915 30 mg suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>SRD Cohort 2: TAK-915 100 mg</title>
          <description>TAK-915 100 mg suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>SRD Cohort 3: TAK-915 200 mg</title>
          <description>TAK-915 200 mg suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>MRD Cohorts Pooled Placebo</title>
          <description>TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.</description>
        </group>
        <group group_id="E6">
          <title>MRD Cohort 5: TAK-915 30 mg</title>
          <description>TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.</description>
        </group>
        <group group_id="E7">
          <title>MRD Cohort 6: TAK-915 100 mg</title>
          <description>TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.</description>
        </group>
        <group group_id="E8">
          <title>MRD Cohort 7: TAK-915 200 mg</title>
          <description>TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.</description>
        </group>
        <group group_id="E9">
          <title>DDI Cohort 8: Midazolam 2 mg</title>
          <description>Midazolam 2 mg suspension, orally, once on Days 1 and 16 (within 15 minutes after last dose of TAK-915).</description>
        </group>
        <group group_id="E10">
          <title>DDI Cohort 8: TAK-915 100 mg</title>
          <description>TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16.</description>
        </group>
        <group group_id="E11">
          <title>DDI Cohort 8: TAK-915 + Midazolam 2 mg</title>
          <description>Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915)</description>
        </group>
        <group group_id="E12">
          <title>BA/FE Cohort Regimen A</title>
          <description>TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of ant period.</description>
        </group>
        <group group_id="E13">
          <title>BA/FE Cohort Regimen B</title>
          <description>TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of any Period.</description>
        </group>
        <group group_id="E14">
          <title>BA/FE Cohort Regimen C</title>
          <description>TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of any period.</description>
        </group>
        <group group_id="E15">
          <title>ESSD Cohort 12: TAK-915 50 mg</title>
          <description>TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version: 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version: 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infrequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takedaâ€™s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

